Vectura Share Discussion Threads

[richtea1701] 21/12/2016 15:22

Give it chance campers

[dontay] 21/12/2016 15:19

Licensing agreement for Utibron/Seebri in the USWed, 21st Dec 2016 13:49RNS Number : 5071SVectura Group plc21 December 2016 Vectura Group plcLicensing agreement signed for the launch of Utibron/Seebri in the US Chippenham, UK - 21 December 2016: Vectura Group plc (LSE: VEC) ("Vectura", "the Group"), an industry-leading inhaled airways disease focused business, reports that Novartis announced today that it has signed a licensing agreement with Sunovion Pharmaceuticals Inc., (MARLBOROUGH, Mass, "Sunovion"), for the US commercial rights to its three treatments for chronic obstructive pulmonary disease ("COPD"), Utibron™ Neohaler® (indacaterol/glycopyrrolate) inhalation powder, Seebri™ Neohaler® (glycopyrrolate) inhalation powder, and Arcapta® Neohaler® (indacaterol) inhalation powder. This license is specific to the US and has no implications outside this market. Novartis will continue to manufacture these medicines for Sunovion. Novartis will also continue to commercialise Ultibro® Breezhaler® (indacaterol/glycopyrronium), Seebri® Breezhaler®(glycopyrronium) and Onbrez® Breezhaler® (indacaterol) to COPD patients outside of the US.Outside the US, Novartis' indacaterol/glycopyrronium formulation Ultibro Breezhaler 110/50 mcg administered once-daily is the leading therapy in sales in its class. In all markets other than the US, Novartis has a full respiratory presence and portfolio and is committed to building category leadership and meeting the evolving needs of patients living with respiratory diseases including asthma and COPD. The COPD portfolio remains a global priority for Novartis.James Ward-Lilley, CEO of Vectura, commented:"We are pleased that Novartis has signed this licensing agreement with Sunovion to bring Seebri and Utibron to the US market. We are confident that with its established US respiratory focus and commercialisation expertise Sunovion will be a strong partner. The launch of these products in 2017 will give doctors new treatment options for their COPD patients. We look forward to the successful US commercialisation of these products and the further contribution they will make to the substantial existing recurring and growing royalty stream we receive from Novartis as reported in our recent interim results."This announcement includes inside informationEnds -

[dp1umb] 21/12/2016 15:03

I must be missing something here,I thought after the last couple of announcements that there would be upward momentum with the share price .My other main investment BTG has struggled in the last eighteen months but I can understand why,but this is very frustrating .

[tcarter66208] 21/12/2016 14:41

Wow what is going on, something must be up, having licences for the US market is def good news. Albeit probably known well before.

[alexchry] 21/12/2016 14:13

Pob-if this is the response to good news, heaven help us if any bad news is announced!

[pooroldboy55] 21/12/2016 13:57

I missed the RNS but doesn't seemed to help much!!

[pooroldboy55] 21/12/2016 13:52

Well it looks like there could be some bad news on the way looking at share price!!!!!!

[cap160] 21/12/2016 13:52

About time. Merry Xmas

[pooroldboy55] 21/12/2016 12:53

Yes should have had some news from company even to say there's no news and all going to plan.

[richtea1701] 20/12/2016 17:15

Once the analysts start cutting targets it's sure to go up - muppet show

[dontay] 20/12/2016 17:10

No report as such just a minor adjustment. StockMarketWire.com - N+1 Singer today reaffirms its buy investment rating on Vectura Group PLC [LON:VEC] and cut its price target to 202p (from 208p).

[fhmktg] 20/12/2016 15:58

Anybody got a link to the N+1 report?

[alexchry] 20/12/2016 13:03

Still no sign of the seven core upcoming news items for 2016 as declared by Vectura on the 23rd of November so I'm not surprised the share price is still in the doldrums. The drop in target price by N+1 Singer is not significant in itself but it is going in the wrong direction. I do hope we hear some good news soon, there has been very little since the takeover/merger was announced.

[a1ord53] 20/12/2016 12:25

Vectura Group Plc : N+1 Singer cuts target price to 202p from 208p
I will be happy to see 160-180p again

[diesel] 14/12/2016 16:17

Been buying more today, think this could be at the lower end of the rising channel, well who knows, but believe this represents a good opportunity at these levels.

[pooroldboy55] 13/12/2016 12:17

Hi alex

Yes we could do with good news lots of news to come but never seems to happen roll on next year.

Cheers POB Hoping for a prosperous new year to all VEC holders

[alexchry] 13/12/2016 10:52

Pob-yes, we could do with some good news and not just from Novartis. In the results presentation Vectura list seven items in upcoming core news flow for 2016. So far, I haven't seen any news so it's no surprise that the share price is weak.

[pooroldboy55] 13/12/2016 08:24

Looks like we are back the on a downward track we sure could do with some good news from Novartis.

[a1ord53] 12/12/2016 23:07

After ex Skp shareholders will finish sell of , I hope share price wil go only up up up :)
The same was after Vec took over German company and german shareholders were selling and selling after they finished sell of share price went up to 200p

[fhmktg] 11/12/2016 23:38

Visited my Centenarian aunt today, who suffers from asthma - good to see that her inhaler is Flutiform!What a recommendation!

[cumnor] 08/12/2016 22:42

Quite significant news and would be surprised if Novartis don't jump at this in a big way. Great for VEC with two majors, incl GSK interested in their non steroid inhalers. They of course have SKPs Fluticasone as well for those who need a steroid. Not as much competition in this market as people think so VEC with mrkt cap of less than a billion will be a big noise in the copd field in a couple of years. Bought in here for Sipp today. imo

[stockrod43] 08/12/2016 19:39

sounds like time for a top up keep watching

[dontay] 08/12/2016 19:09

Ultibro Breezhaler is currently approved for use in over 90 countries worldwide, including countries within the EU and Latin America, Japan, Canada, Switzerland and Australia... in total it's already in a huge market.Obviously the big hope is that it'll get launched on the USA market as well and that should provide some consolidation and strengthen the share price .. but I'm not sure it will actually leap up by much in one go. Realistically I think a nicely rising trend leading into next year is probably the more likely scenario.Is there any plans/timescale to also get it into China?